478163-07-4

Basic information

• Product Name: Benzenemethanol, 2-fluoro-, methanesulfonate
• CAS NO: 478163-07-4
• Molecular Formula: C8H9FO3S
• Molecular Weight: 204.222
• Mol File: 478163-07-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 2-fluoro-, methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-fluoro-, methanesulfonate(478163-07-4)
• EPA Substance Registry System: Benzenemethanol, 2-fluoro-, methanesulfonate(478163-07-4)

Safety Data

• Hazardous Substances Data: 478163-07-4(Hazardous Substances Data)

Upstream product

• 446-51-5 2-fluorobenzyl alcohol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 62284-30-4 2-fluorobenzyl azide 
• 478162-56-0 4-[4-(2-(N-(2-fluorobenzyl)-N-methylamino)ethoxy)phenyl]-4-oxobutyric acid 
• 478163-10-9 tert-butyl 4-[4-(2-(N-(2-fluorobenzyl)-N-methylamino)ethoxy)phenyl]-4-oxobutyrate 
• 478163-09-6 4-(2-(N-(2-fluorobenzyl)-N-methylamino)ethoxy)acetophenone 
• 478163-08-5 2-(N-(2-fluorobenzyl)-N-methylamino)ethyl chloride 
• 1446359-93-8 C₁₄H₁₁FN₄OS 
• 326-62-5 2-fluorophenyl acetonitrile 
• 93748-83-5 2-(N-(2-fluorobenzyl)-N-methylamino)ethanol 

Relevant articles and documents

Synthesis of cinnamic acid derivatives and leishmanicidal activity against Leishmania braziliensis

Leishmania braziliensis is one of the pathogenic agents of cutaneous and mucocutanoeous leishmaniasis. There are no validated vaccines to prevent the infection and the treatment relies on drugs that often present severe side effects, which justify the efforts to find new potential antileishmanial drugs. An alternative to promote the discovery of new drugs would be the association of different chemical groups of bioactive compounds. Here we describe the synthesis and bioactivity evaluation against L. braziliensis of cinnamic acid derivatives possessing isobenzofuranone and 1,2,3-triazole functionalities. We tested 25 compounds at 10 μM concentration against extracellular promastigotes and intracellular amastigotes during macrophage infection. Most compounds were more active against amastigotes than to promastigotes. The derivatives (E)-3-oxo-1,3-dihydroisobenzofuran-5-yl-(3,4,5-trimethoxy) cinnamate (5c), (1-(3,4-difluorobenzyl)-1H-1,2,3-triazol-4-yl)methyl cinnamate (9g), and (1-(2-bromobenzyl)-1H-1,2,3-triazol-4-yl)methyl cinnamate (9l) were the most effective presenting over 80% toxicity on L. braziliensis amastigotes. While compound 5c is a cinnamate with an isobenzofuranone portion, 9g and 9l are triazolic cinnamic acid derivatives. The action of these compounds was comparable to amphotericin B used as positive control. Ultrastructural analysis revealed that 5c-treated parasites showed impaired cytokinesis and apoptosis triggering. Taken together, these results highlight the potential of cinnamic acid derivatives in development of novel anti-leishmanial drugs.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).